Guest Posted June 22, 2010 Posted June 22, 2010 Analysts predict between £50m and £60m of peak annual sales for Sativex by 2015, with GW receiving between 20 and 30 per cent of that. The approval of Sativex provides a boost to GW’s development programme to create other cannabis-based medicines. Trials are already underway on cannabis-based medicines to treat epilepsy and psychosis, and GW is seeking approval from US regulators for the marketing of Sativex as a treatment for cancer pain http://www.ft.com/cms/s/0/1e5e5e06-7d2f-11df-8845-00144feabdc0.html Quote
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.